These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36516312)

  • 1. Plasma-derived factor VIIa and factor X mixture agent (MC710) prophylaxis in haemophilia B patients with inhibitors.
    Sakai M; Amano K; Chin M; Takedani H; Ishida H; Sakashita K; Taki M; Migita M; Watanabe H; Ishimura M; Nogami K; Harano S; Shirahata A
    Haemophilia; 2023 Mar; 29(2):456-465. PubMed ID: 36516312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
    Shirahata A; Fukutake K; Takamatsu J; Shima M; Hanabusa H; Mugishima H; Amano K; Takedani H; Tamashima S; Matsushita T; Tawa A; Tanaka I; Higasa S; Kosaka Y; Fujii T; Sakai M; Migita M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2013 Nov; 19(6):853-60. PubMed ID: 23738888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.
    Shinkoda Y; Shirahata A; Fukutake K; Takamatsu J; Shima M; Hanabusa H; Mugishima H; Takedani H; Kawasugi K; Taki M; Matsushita T; Tawa A; Nogami K; Higasa S; Kosaka Y; Fujii T; Sakai M; Migita M; Uchiba M; Kawakami K; Sameshima K; Ohashi Y; Saito H
    Haemophilia; 2017 Jan; 23(1):59-66. PubMed ID: 27480904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report.
    Shirahata A; Fukutake K; Mimaya J; Takamatsu J; Shima M; Hanabusa H; Takedani H; Takashima Y; Matsushita T; Tawa A; Higasa S; Takata N; Sakai M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2013 Mar; 19(2):330-7. PubMed ID: 22989180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors--phase I trial.
    Shirahata A; Fukutake K; Mimaya J; Takamatsu J; Shima M; Hanabusa H; Takedani H; Takashima Y; Matsushita T; Tawa A; Higasa S; Takata N; Sakai M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2012 Jan; 18(1):94-101. PubMed ID: 21535327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors.
    Shirayama R; Takedani H; Chikasawa Y; Ishiguro A; Ishimura M; Isobe K; Uchiba M; Ogata Y; Kakuda H; Kusuhara K; Shirahata A
    Blood Coagul Fibrinolysis; 2019 Dec; 30(8):385-392. PubMed ID: 31738288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.
    Chai-Adisaksopha C; Nevitt SJ; Simpson ML; Janbain M; Konkle BA
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011441. PubMed ID: 28944952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.
    Antunes SV; Tangada S; Stasyshyn O; Mamonov V; Phillips J; Guzman-Becerra N; Grigorian A; Ewenstein B; Wong WY
    Haemophilia; 2014 Jan; 20(1):65-72. PubMed ID: 23910578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.
    Coppens M; Pipe SW; Miesbach W; Astermark J; Recht M; van der Valk P; Ewenstein B; Pinachyan K; Galante N; Le Quellec S; Monahan PE; Leebeek FWG;
    Lancet Haematol; 2024 Apr; 11(4):e265-e275. PubMed ID: 38437857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.
    Young G; Srivastava A; Kavakli K; Ross C; Sathar J; You CW; Tran H; Sun J; Wu R; Poloskey S; Qiu Z; Kichou S; Andersson S; Mei B; Rangarajan S
    Lancet; 2023 Apr; 401(10386):1427-1437. PubMed ID: 37003287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.
    Srivastava A; Rangarajan S; Kavakli K; Klamroth R; Kenet G; Khoo L; You CW; Xu W; Malan N; Frenzel L; Bagot CN; Stasyshyn O; Chang CY; Poloskey S; Qiu Z; Andersson S; Mei B; Pipe SW
    Lancet Haematol; 2023 May; 10(5):e322-e332. PubMed ID: 37003278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
    Scharrer I
    Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.
    Wang M; Lawrence JB; Quon DV; Ducore J; Simpson ML; Boggio LN; Mitchell IS; Yuan G; Alexander WA; Schved JF
    Haemophilia; 2017 Nov; 23(6):832-843. PubMed ID: 28776894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
    Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
    Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
    Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
    Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
    Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
    Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.
    Ducore J; Lawrence JB; Simpson M; Boggio L; Bellon A; Burggraaf J; Stevens J; Moerland M; Frieling J; Reijers J; Wang M
    Haemophilia; 2017 Nov; 23(6):844-851. PubMed ID: 28984010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients.
    Xi Y; Jin C; Liu W; Zhou H; Wang Z; Zhou R; Lou S; Zhao X; Chen F; Cheng P; Sun Z; Jia H; Zhang L
    Haemophilia; 2022 Nov; 28(6):e219-e227. PubMed ID: 35996199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.